Loading...

477 posters, 14 topics, 2,065 authors, 1,055 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

The Joint EBJIS-MSIS 2026 Conference

17 - 19 September, 2026 | Porto, Portugal

The Joint EBJIS-MSIS 2026 Conference banner

EP411

The Double-Edged Sword of Antimicrobials: A Case of Successful PJI Eradication Following Severe Hypersensitivity and Thrombocytopenia

Part of Topic

Prosthetic Joint Infections

Periprosthetic joint infection complicates up to 3% of all arthroplasties. Staphylococcus lugdunensis, although a coagulase-negative staphylococcus, shares adhesins, biofilm formation and tissue-destructive toxins with S. aureus and behaves far more aggressively than other skin commensals, with high relapse rates unless the implant is removed.

What’s more, the cure is harder when the soft-tissue envelope is compromised. Elephantiasis nostras verrucosa is a rare consequence of chronic non-filarial lymphoedema, driven by obesity, venous insufficiency and repeated cellulitis, in which dermal fibrosis and hyperkeratosis leave a fragile limb that both predisposes to infection and hampers wound healing.

Antimicrobial therapy, especially if is a long-term regimen, can be  hazardous: adverse events occurred in 73 of 80 patients in a prospective PJI series. Cotrimoxazole is a well-recognised cause of drug-induced immune thrombocytopenia that can lead to life threatening bleeding symptoms.

 

 

•A two-stage revision TKA eradicated a S. lugdunensis knee PJI in an 82-year-old with elephantiasis nostras verrucosa and multiple comorbidities.
•Antimicrobials cut both ways: a bullous rash and then immune thrombocytopenia with platelets <10 000 interrupted a standard-duration course.
•Prompt withdrawal and a switch to doxycycline and rifampicin allowed cure without compromising the surgical plan and any long-term consequences for the patient.
ebjis-msis2026 banner
Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.